智通财经网·2025-12-10 08:11Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received approval from the National Medical Products Administration for the marketing license of SPH3127 tablets, a new oral non-peptide small molecule renin inhibitor for the treatment of primary hypertension [1] Company Summary - The approved drug, SPH3127, is designed to directly inhibit renin, counteracting the blood pressure increase caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - Clinical studies have demonstrated that SPH3127 shows a clear antihypertensive effect in patients with primary hypertension, providing a new treatment option for this patient group [1] - The total research and development investment for SPH3127 has reached approximately 296 million yuan [1] Industry Summary - SPH3127 is positioned as a next-generation treatment in the hypertension market, with stronger renin activity inhibition compared to existing drugs targeting the same pathway [1] - The drug has shown efficacy in models of hypertension, chronic kidney disease, and inflammatory bowel disease, indicating its potential broader therapeutic applications [1]